Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 2/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 2/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | DHODH | Q02127 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperine SCHEMBL11434404 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL94058 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL29369346 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL5309092 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| SCHEMBL17340450 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL14171509 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL13151642 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL119081 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL29358781 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 | |
| Piperine SCHEMBL94059 | 1.00 | MAOB (1.00) | MAOBHPGDKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265606-B1 | FIBROUS ELEMENTS, FIBROUS STRUCTURES, AND PRODUCTS COMPRISING A DETERRENT AGENT AND METHODS FOR MAKING SAME | PROCTER & GAMBLE (US) | 2025-06-04 | — | — | EP | claimed |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2024-08-29 | — | — | US | claimed |
| EP-3525825-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN | CIPLA LTD (IN) | 2024-03-20 | — | — | EP | claimed |
| EP-3494104-B1 | WARMING SENSATION COMPOUNDS | TAKASAGO PERFUMERY CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| EP-3463326-B1 | COMPOSITIONS AND METHODS FOR IMPROVING HYDRATION OF INDIVIDUALS HAVING DYSPHAGIA | NESTLE SA (CH) | 2023-09-20 | — | — | EP | claimed |
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| US-20230119206-A1 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | CIPLA LIMITED (IN) | 2023-04-20 | — | — | US | claimed |
| US-20220193043-A1 | Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and Piperine | CIPLA LIMITED (IN) | 2022-06-23 | — | — | US | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | CIPLA LIMITED (IN) | 2022-04-14 | — | — | US | claimed |
| EP-3946267-A1 | PHARMACEUTICAL COMBINATION FORMULATIONS COMPRISING TIZANIDINE, RESVERATROL AND PIPERINE | Cipla Limited (IN) | 2022-02-09 | — | — | EP | claimed |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | CIPLA LIMITED (IN) | 2022-02-01 | — | — | US | claimed |
| EP-3525825-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIFAXIMIN | CIPLA LTD (IN) | 2024-03-20 | — | — | EP | disclosed |
| CN-110087688-B | Pharmaceutical composition comprising rifaximin | 希普拉有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20230119206-A1 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | CIPLA LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| US-11612612-B2 | Pharmaceutical compositions | CIPLA LIMITED (IN) | 2023-03-28 | — | — | US | disclosed |
| EP-4025700-A1 | NUCLEIC ACIDS, PROTEINS AND PROCESSES FOR PRODUCING PIPERINE AND OTHER AMIDES | Leibniz-Institut für Pflanzenbiochemie (IPB) (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-20220130493-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-28 | — | — | US | disclosed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | disclosed |
| US-11267798-B2 | Process for the preparation of piperine | CIPLA LIMITED (IN) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612612-B2 | Pharmaceutical compositions | HAVCR2, APOB, ABCB11 | MAOB 772/4885HPGD 1205/4885KDM4E 3672/4885 |
| US-20230119206-A1 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | BCL6B, BCL9, BCL6 | MAOB 1034/4885HPGD 2887/4885KDM4E 1527/4885 |
| US-11234981-B2 | Combination therapy for use in treating retroviral infections | PAICS, HAVCR2, THPO | MAOB 730/4885HPGD 2355/4885KDM4E 4050/4885 |
| US-20220193043-A1 | Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and Piperine | CPT1B, GABRR2, SLC6A11 | MAOB 1988/4885HPGD 577/4885KDM4E 1055/4885 |
| US-11267798-B2 | Process for the preparation of piperine | PTMA, ITPA, PRPH | MAOB 996/4885HPGD 1264/4885KDM4E 2056/4885 |
| US-20220110938-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | MAOB 730/4885HPGD 2355/4885KDM4E 4050/4885 |
| US-20240285629-A1 | Combination Therapy for Use in Treating Retroviral Infections | PAICS, HAVCR2, THPO | MAOB 730/4885HPGD 2355/4885KDM4E 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.